Biomarker for distinguishing clinical subtypes of hyperuricemia and application

By identifying 12 SNP sites as biomarkers in primary gout patients, accurately distinguishing the clinical subtypes of hyperuricemia, the problem of poor treatment effect in the prior art is solved, and targeted treatment and better healthy recovery are achieved.

CN119530372AActive Publication Date: 2025-02-28CHARLIE GAUTE (QINGDAO) HEALTH TECH CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411616498.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-11-13
Filing Date
2024-11-13
Publication Date
2025-02-28
Estimated Expiration
2044-11-13

AI Technical Summary

Technical Problem

The prior art is difficult to accurately identify the clinical subtype of hyperuricemia, resulting in poor treatment results and affecting the patient's health status and quality of life.

Method used

By conducting phenotype and genotypic studies in patients with primary gout, 12 specific SNP sites were identified as biomarkers to distinguish between hyperuricemia, poor renal excretion, mixed and other types of hyperuricemia.

Benefits of technology

Accurately distinguish the clinical subtypes of hyperuricemia, provide targeted treatment plans, improve treatment effects, and promote patients' health recovery and quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119530372A_ABST
    Figure CN119530372A_ABST
Patent Text Reader

Abstract

The invention provides a biomarker for distinguishing clinical subtypes of hyperuricemia and application of the biomarker, and relates to the technical field of biomedicine. The biomarker for distinguishing the clinical subtypes of the hyperuricemia comprises one or more SNP (Single Nucleotide Polymorphism) loci in rs2231142, rs3775948, rs11231463, rs7928514, rs57633992, rs4072037, rs11227805, rs7679724, rs671, rs73436803, rs1260326 and rs641811, and is characterized in that the one or more SNP loci in the rs2231142, the rs3775948, the rs11231463, the rs7928514, the rs57633992, the rs4072037, the Clinical subtypes of hyperuricemia include kidney hyperloading type, kidney dysexcretion type, mixed type and other types. The specific subtype of a hyperuricemia patient can be accurately distinguished in actual clinical application by utilizing the biomarker, targeted treatment is carried out, and the treatment progress can be accelerated.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to Chinese patent "Biomarkers and applications for distinguishing clinical subtypes of hyperuricemia" with application date of November 13, 2023 and application number 202311506400.5, the entire contents of which are incorporated by reference into this application. Technical Field

[0002] The present application relates to the field of biomedical technology, and in particular to biomarkers and applications for distinguishing clinical subtypes of hyperuricemia. Background Art

[0003] Hyperuricemia (HUA) is a metabolic disease that threatens human health and is also one of the independent risk factors for hypertension, diabetes, cardiovascular disease, chronic kidney disease and other diseases. The onset of hyperuricemia is mostly caused by increased uric acid and reduced excretion. Uric acid crystals deposited in joints or soft tissues can induce acute arthritis or tophi. Clinical manifestations are sodium urate (MSU) crystals in joint tissues, surrounded by chronic granulomatous inflammatory tissues.

[0004] Gout and hyperuricemia are closely related, and hyperuricemia is the most important risk factor for gout. Gout usually causes patients to suffer from repeated attacks of arthritis symptoms, accompanied by hypertension, arteriosclerosis, kidney disease and other symptoms. If not treated effectively in time, it will have a serious adverse effect on the patient's health and daily quality of life. Therefore, after hyperuricemia is clinically diagnosed, effective treatment should be carried out in time to prevent the disease from worsening and causing adverse consequences (References: [1] Yang Xiaomei, Yang Yong, Luo Ying, et al. Clinical efficacy of Jiawei Siwu Decoction combined with Western medicine in the treatment of patients with gout and hyperuricemia [J]. Chinese and Foreign Medical Treatment, 2023, 42(14): 27-30+35. DOI: 10.16662 / j.cnki.1674-0742.2023.14.027.). At present, clinical trials have shown that the effect of medication based on classification may be better.

[0005] Genome-wide association studies (GWAS) have also identified many genetic variants associated with the control of uric acid levels and the risk of gout. The etiological variants of hyperuricemia mainly involve genes for renal and extrarenal uric acid transporters or their regulators, as well as genes for uric acid synthesis, which have identified the kidney, intestine, and liver as sites of uric acid regulation. Some variants are universal, but most are ethnic-specific. Some loci involved in inflammatory pathways have been identified as being associated with the onset and prognosis of gout.

[0006] Hyperuricemia can be divided into four subtypes according to 24-hour uric acid excretion (UUE) and fractional uric acid excretion (FEUA): renal overload subtype (ROL), renal underexcretion subtype (RUE), combined subtype, and normal subtype (references: [2] Decreased extra-renal urate excretion is a common cause of hyperuricemia. [J]. Nature communications, 2012. DOI: 10.1038 / ncomms1756.; [3] Budd R C. Kelley and Firestein's Textbook of Rheumatology [J]. 2017: 1973-1982. DOI: 10.1016 / B978-0-323-31696-5.00116-9.). To date, the clinical characteristics and genetic basis of these subtypes have not been explored in detail, and it is still unclear whether these four clinical subtypes have clinical phenotypes mediated by specific genetic backgrounds.

[0007] Accurately identifying individuals with hyperuricemia may help prevent and treat hyperuricemia and its related diseases. Therefore, there is an urgent need to find biomarkers with high specificity and accuracy to classify hyperuricemia and guide the treatment process of hyperuricemia. Summary of the invention

[0008] In this application, it is assumed that multiple genetic variations may work together to establish unique clinical characteristics, so phenotypic and genotypic studies of different clinical classifications of hyperuricemia were conducted in patients with primary gout to better guide the treatment process of gout patients with different indications.

[0009] Since gout and hyperuricemia are closely related, hyperuricemia is the most important risk factor for gout. Therefore, there are many hyperuricemia patients among gout patients, but not all gout patients have hyperuricemia. Therefore, it is necessary for gout patients to distinguish different indications and then treat them. There are also reports that the severity of gout in patients is also related to their hyperuricemia subtype, which further shows the importance of determining the hyperuricemia subtype of gout in patients.

[0010] Specifically, in this application, a clinical cross-sectional study was conducted on 5383 gout patients in two geographically isolated centers in China from 2016 to 2022 to explore the phenotypic and genotypic characteristics between hyperuricemia subtypes. According to urinary uric acid excretion and uric acid excretion fraction, hyperuricemia was defined as renal overload (ROL) type, renal poor excretion (RUE) type, mixed type or other types.

[0011] On the one hand, the present application provides a biomarker for distinguishing clinical subtypes of hyperuricemia, wherein the clinical subtypes of hyperuricemia include renal overload type, renal poor excretion type, mixed type and other types, wherein the biomarker includes at least one SNP site from SNP1 site to SNP12 site;

[0012] The rs number of SNP1 site is rs2231142, the rs number of SNP2 site is rs3775948, the rs number of SNP3 site is rs11231463, the rs number of SNP4 site is rs7928514, the rs number of SNP5 site is rs57633992, the rs number of SNP6 site is rs4072037, the rs number of SNP7 site is rs11227805, the rs number of SNP8 site is rs7679724, the rs number of SNP9 site is rs671, the rs number of SNP10 site is rs73436803, the rs number of SNP11 site is rs1260326, and the rs number of SNP12 site is rs641811.

[0013] The clinical subtypes of hyperuricemia include renal overload type, renal poor excretion type, mixed type and other types, among which the hyperuricemia subtype is defined as: UUE>600mg / d / 1.73m 2 , FEUA ≥ 5.5% is considered as renal overload type, UUE ≤ 600 mg / d / 1.73 m 2 , FEUA < 5.5% is poor renal excretion type, UUE > 600 mg / d / 1.73 m 2 , FEUA < 5.5% is mixed type, UUE ≤ 600 mg / d / 1.73 m 2 , FEUA ≥ 5.5% is other types.

[0014] The rs number of SNP1 locus is rs2231142, located on the ABCG2 gene, with the risk gene being T and the non-risk gene being G;

[0015] The rs number of SNP2 locus is rs3775948, located on the SLC2A9 gene, with the risk gene as G and the non-risk gene as C;

[0016] The rs number of SNP3 is rs11231463, located on the SLC22A9 gene, with the risk gene as G and the non-risk gene as A;

[0017] The rs number of SNP4 is rs7928514, located on the PLA2G16 gene, with the risk gene being A and the non-risk gene being G;

[0018] The rs number of SNP5 is rs57633992, located on the NRXN2 / URAT1 gene, with the risk gene as A and the non-risk gene as C;

[0019] The rs number of SNP6 is rs4072037, located on the MUC1 gene, with the risk gene as T and the non-risk gene as C;

[0020] The rs number of SNP7 is rs11227805, which is located on the AIP gene, with the risk gene being T and the non-risk gene being G;

[0021] The rs number of SNP8 is rs7679724, located on the SLC2A9 gene, with the risk gene as T and the non-risk gene as G;

[0022] The rs number of SNP9 is rs671, which is located on the ALDH2 gene, with the risk gene being G and the non-risk gene being A;

[0023] The rs number of SNP10 is rs73436803, located on the COMM4 gene, with the risk gene as C and the non-risk gene as T;

[0024] The rs number of SNP11 is rs1260326, located on the GCKR gene, with the risk gene as T and the non-risk gene as C;

[0025] The rs number of SNP12 is rs641811. It is located on the FLRT1 gene, the risk gene is A, and the non-risk gene is G.

[0026] Furthermore, the biomarkers include:

[0027] A first biomarker combination for identifying kidney overload type, wherein the first biomarker combination includes at least one SNP site among SNP1, SNP2, SNP3, SNP4, SNP5, and SNP6;

[0028] A second biomarker combination for identifying poor renal excretion type, wherein the second biomarker combination includes at least one SNP site among SNP1, SNP2, SNP3, SNP4, SNP5, SNP6, SNP8, SNP9, SNP10, and SNP12;

[0029] A third biomarker combination for identifying a mixed type, wherein the third biomarker combination includes at least one SNP site among SNP1, SNP2, SNP4, SNP5, SNP6, SNP11, and SNP12;

[0030] A fourth biomarker combination for identifying other types, wherein the fourth biomarker combination includes at least one SNP site among SNP1, SNP2, SNP3, and SNP4.

[0031] Preferably, the biomarkers include:

[0032] A first biomarker combination for identifying kidney overload type, wherein the first biomarker combination consists of SNP1, SNP2, SNP3, SNP4, SNP5 and SNP6;

[0033] A second biomarker combination for identifying renal malabsorption, wherein the second biomarker combination consists of SNP1, SNP2, SNP3, SNP4, SNP5, SNP6, SNP8, SNP9, SNP10 and SNP12;

[0034] a third biomarker combination for identifying a mixed type, wherein the third biomarker combination consists of SNP1, SNP2, SNP4, SNP5, SNP6, SNP11 and SNP12;

[0035] A fourth biomarker combination for identifying other types, wherein the fourth biomarker combination consists of SNP1, SNP2, SNP3 and SNP4.

[0036] Preferably, the present application provides biomarkers for distinguishing clinical subtypes of hyperuricemia in patients with primary gout.

[0037] On the other hand, the present application also provides primers or probes for detecting the above-mentioned biomarkers, wherein the primers use the nucleotide sequence where the biomarker is located as the target sequence and are used for specific amplification of the target sequence; and the probes specifically capture the nucleotide sequence where the biomarker is located.

[0038] The SNP1 specific amplification primer pair includes a forward primer with a nucleotide sequence as shown in SEQ ID NO.1, a reverse primer with a nucleotide sequence as shown in SEQ ID NO.2, and an extension primer with a nucleotide sequence as shown in SEQ ID NO.3;

[0039] The SNP2 specific amplification primer pair includes a forward primer with a nucleotide sequence as shown in SEQ ID NO.4, a reverse primer with a nucleotide sequence as shown in SEQ ID NO.5, and an extension primer with a nucleotide sequence as shown in SEQ ID NO.6;

[0040] The SNP3 specific amplification primer pair includes a forward primer with a nucleotide sequence as shown in SEQ ID NO.7, a reverse primer with a nucleotide sequence as shown in SEQ ID NO.8, and an extension primer with a nucleotide sequence as shown in SEQ ID NO.9;

[0041] The SNP4-specific amplification primer pair includes a forward primer with a nucleotide sequence as shown in SEQ ID NO.10, a reverse primer with a nucleotide sequence as shown in SEQ ID NO.11, and an extension primer with a nucleotide sequence as shown in SEQ ID NO.12;

[0042] The SNP5 specific amplification primer pair includes a forward primer with a nucleotide sequence as shown in SEQ ID NO.13, a reverse primer with a nucleotide sequence as shown in SEQ ID NO.14, and an extension primer with a nucleotide sequence as shown in SEQ ID NO.15;

[0043] The SNP6 specific amplification primer pair includes a forward primer with a nucleotide sequence as shown in SEQ ID NO.16, a reverse primer with a nucleotide sequence as shown in SEQ ID NO.17, and an extension primer with a nucleotide sequence as shown in SEQ ID NO.18;

[0044] The SNP7 specific amplification primer pair includes a forward primer with a nucleotide sequence as shown in SEQ ID NO.19, a reverse primer with a nucleotide sequence as shown in SEQ ID NO.20, and an extension primer with a nucleotide sequence as shown in SEQ ID NO.21;

[0045] The SNP8 specific amplification primer pair includes a forward primer with a nucleotide sequence as shown in SEQ ID NO.22, a reverse primer with a nucleotide sequence as shown in SEQ ID NO.23, and an extension primer with a nucleotide sequence as shown in SEQ ID NO.24;

[0046] The SNP9-specific amplification primer pair includes a forward primer having a nucleotide sequence as shown in SEQ ID NO.25, a reverse primer having a nucleotide sequence as shown in SEQ ID NO.26, and an extension primer having a nucleotide sequence as shown in SEQ ID NO.27;

[0047] The SNP10 specific amplification primer pair includes a forward primer having a nucleotide sequence as shown in SEQ ID NO.28, a reverse primer having a nucleotide sequence as shown in SEQ ID NO.29, and an extension primer having a nucleotide sequence as shown in SEQ ID NO.30;

[0048] The SNP11 specific amplification primer pair includes a forward primer with a nucleotide sequence as shown in SEQ ID NO.31, a reverse primer with a nucleotide sequence as shown in SEQ ID NO.32, and an extension primer with a nucleotide sequence as shown in SEQ ID NO.33;

[0049] The SNP12 specific amplification primer pair includes a forward primer with a nucleotide sequence as shown in SEQ ID NO.34, a reverse primer with a nucleotide sequence as shown in SEQ ID NO.35, and an extension primer with a nucleotide sequence as shown in SEQ ID NO.36.

[0050] In a preferred embodiment, the primer combination for detecting the above-mentioned biomarkers includes:

[0051] A first primer combination for specifically amplifying SNP sites associated with kidney overload, wherein the first primer combination includes specific amplification primer pairs of SNP1, SNP2, SNP3, SNP4, SNP5 and SNP6;

[0052] A second primer combination for specifically amplifying a SNP site associated with poor renal excretion, wherein the second primer combination includes a specific amplification primer pair among SNP1, SNP2, SNP3, SNP4, SNP5, SNP6, SNP8, SNP9, SNP10 and SNP12;

[0053] A third primer combination for specifically amplifying mixed-type related SNP sites, wherein the third primer combination includes specific amplification primer pairs of SNP1, SNP2, SNP4, SNP5, SNP6, SNP11 and SNP12;

[0054] The fourth primer combination is used for specific amplification of other type-related SNP sites, and the fourth primer combination includes specific amplification primer pairs of SNP1, SNP2, SNP3 and SNP4.

[0055] On the other hand, the present application also provides a kit for distinguishing clinical subtypes of hyperuricemia, wherein the kit contains the primers or probes as described above.

[0056] Furthermore, the kit also includes reagents used in any one of or a combination of fluorescent PCR, PCR amplification, digital PCR, liquid phase chip, second-generation sequencing, and third-generation sequencing.

[0057] On the other hand, the present application also provides the use of the above-mentioned biomarkers or the above-mentioned primers or probes or the above-mentioned kits in the preparation of products for distinguishing clinical subtypes of hyperuricemia.

[0058] In a preferred embodiment, the present application also provides a method for distinguishing clinical subtypes of hyperuricemia, the method comprising the following steps:

[0059] (a) obtaining SNP1-12 locus genes in a sample to be tested; (b) determining the clinical subtype of hyperuricemia of an individual based on the detection results of the SNP1-12 locus genes.

[0060] Specifically, if the genetic test results of SNP1, SNP2, SNP3, SNP4, SNP5 and SNP6 are all risk genes, and the remaining SNPs are not risk genes, the clinical subtype of hyperuricemia is renal overload type;

[0061] If the genetic test results of SNP1, SNP2, SNP3, SNP4, SNP5, SNP6, SNP8, SNP9, SNP10 and SNP12 are all risk genes, and the remaining SNPs are not risk genes, the clinical subtype of hyperuricemia is poor renal excretion type;

[0062] If the genetic test results of SNP1, SNP2, SNP4, SNP5, SNP6, SNP11, and SNP12 are all risk genes, and the remaining SNPs are not risk genes, the clinical subtype of hyperuricemia is mixed type;

[0063] If the genetic test results of SNP1, SNP2, SNP3 and SNP4 are all risk genes, and the remaining SNPs are not risk genes, then the clinical subtype of hyperuricemia is other types.

[0064] Preferably, the remaining SNP sites are risk-free genes.

[0065] On the other hand, the present application also provides a model for distinguishing clinical subtypes of hyperuricemia, characterized in that the model includes: a data acquisition module, at least for acquiring a sample data set; a sequencing module, at least for obtaining sequencing data of samples such as the above-mentioned biomarkers; a data comparison module, at least for comparing the sequencing data with a reference sequence; and a result determination module, at least for calculating a prediction score threshold through statistical model analysis to determine the clinical subtype of hyperuricemia in the sample to be tested.

[0066] In a preferred embodiment, the sample is a liquid sample, and the biomarker is obtained from the liquid sample, and the liquid sample is mammalian blood and other liquid samples of biological origin, such as peripheral blood, serum, plasma, ascites, urine, cerebrospinal fluid, sputum, saliva, etc.; preferably, peripheral blood and serum. The mammals include rats, mice and humans; preferably, humans; more preferably, the humans are primary gout patients.

[0067] In a preferred embodiment, the model includes: a data acquisition module, at least for acquiring a sample data set; a sequencing module, at least for obtaining gene sequencing data of the sample SNP1-12 sites; a data comparison module, at least for comparing the sequencing data with the risk gene sequence of the SNP1-12 sites; a result determination module, at least for determining whether the gene of the sample SNP1-12 site is a risk gene through statistical model analysis, and thereby obtaining the clinical subtype of hyperuricemia of the sample to be tested.

[0068] Furthermore, the clinical subtypes of hyperuricemia include renal overload type, renal poor excretion type, mixed type and other types.

[0069] Specifically, if the genetic test results of SNP1, SNP2, SNP3, SNP4, SNP5 and SNP6 are all risk genes, and the remaining SNPs are not risk genes, the clinical subtype of hyperuricemia is renal overload type;

[0070] If the genetic test results of SNP1, SNP2, SNP3, SNP4, SNP5, SNP6, SNP8, SNP9, SNP10 and SNP12 are all risk genes, and the remaining SNPs are not risk genes, the clinical subtype of hyperuricemia is poor renal excretion type;

[0071] If the genetic test results of SNP1, SNP2, SNP4, SNP5, SNP6, SNP11, and SNP12 are all risk genes, and the remaining SNPs are not risk genes, the clinical subtype of hyperuricemia is mixed type;

[0072] If the genetic test results of SNP1, SNP2, SNP3 and SNP4 are all risk genes, and the remaining SNPs are not risk genes, then the clinical subtype of hyperuricemia is other types.

[0073] In a preferred embodiment, a model for determining kidney overload type, the model includes: a data acquisition module, at least for acquiring a sample data set; a sequencing module, at least for obtaining gene sequencing data of sample SNP1, SNP2, SNP3, SNP4, SNP5 and SNP6 sites; a data comparison module, at least for comparing the sequencing data with the risk gene sequences of SNP1, SNP2, SNP3, SNP4, SNP5 and SNP6 sites to obtain the number of risk alleles (0, 1 or 2); a result determination module, at least for analyzing through a statistical model, using the formula PRS=SNP(0,1,2)×logOR to calculate the sum of SNP1, SNP2, SNP3, SNP4, SNP5 and SNP6 PRS, and comparing it with the kidney overload type threshold to determine whether the gene of the sample is a kidney overload type risk gene.

[0074] The renal overload thresholds include: when PRS < 1.71, it is low risk; PRS between 1.71-2.19 is medium risk; PRS > 2.19 is high risk.

[0075] In a preferred embodiment, a determination model for renal malabsorption type, the model comprises: a data acquisition module, at least for acquiring a sample data set; a sequencing module, at least for obtaining gene sequencing data of sample SNP1, SNP2, SNP3, SNP4, SNP5, SNP6, SNP8, SNP9, SNP10 and SNP12 sites; a data comparison module, at least for comparing the sequencing data with the risk gene sequence of SNP1, SNP2, SNP3, SNP4, SNP5, SNP6, SNP8, SNP9, SNP10 and SNP12 sites to obtain the number of risk alleles (0, 1 or 2); a result determination module, at least for calculating SNP1, SNP2, SNP3, SNP4, SNP5, SNP6, SNP8, SNP9, SNP10 and SNP12 by statistical model analysis using the formula PRS=SNP(0,1,2)×logOR The sum of the PRS is compared with the renal malabsorption type threshold to determine whether the gene of the sample is a renal malabsorption type risk gene.

[0076] The thresholds for renal poor excretion type include: when PRS < 2.95, it is low risk; when PRS is between 2.95-3.36, it is medium risk; and when PRS is > 3.36, it is high risk.

[0077] In a preferred embodiment, a mixed type determination model, the model includes: a data acquisition module, at least for acquiring a sample data set; a sequencing module, at least for obtaining gene sequencing data of sample SNP1, SNP2, SNP4, SNP5, SNP6, SNP11 and SNP12 sites; a data comparison module, at least for comparing the sequencing data with the risk gene sequences of SNP1, SNP2, SNP4, SNP5, SNP6, SNP11 and SNP12 sites to obtain the number of risk alleles (0, 1 or 2); a result determination module, at least for analyzing through a statistical model, using the formula PRS=SNP(0,1,2)×logOR to calculate the sum of SNP1, SNP2, SNP4, SNP5, SNP6, SNP11 and SNP12 PRS, and comparing it with the mixed type threshold to determine whether the gene of the sample is a mixed type risk gene.

[0078] The mixed thresholds include: when PRS < 1.85, it is low risk; when PRS is between 1.85-2.27, it is medium risk; and when PRS > 2.27, it is high risk.

[0079] On the other hand, the present application further provides an information data processing terminal, characterized in that the information data processing terminal includes a memory, a processor, and a computer program stored in the memory and executable on the processor, characterized in that when the processor executes the computer program, the following steps are implemented:

[0080] (a) obtaining sequencing data of the above-mentioned biomarkers in the sample to be tested; (b) calculating the score by constructing a logistic regression model; (c) determining the clinical subtype of hyperuricemia according to the score.

[0081] On the other hand, the present application further provides a computer-readable storage medium, characterized in that a computer program is stored on the storage medium, and when the computer program is executed by a processor, the following steps are implemented:

[0082] (a) obtaining sequencing data of the above-mentioned biomarkers in the sample to be tested; (b) calculating the score by constructing a logistic regression model; (c) determining the clinical subtype of hyperuricemia according to the score.

[0083] The present invention has the following beneficial effects:

[0084] 1. The present application provides 12 biomarkers and corresponding primer combinations for distinguishing clinical subtypes of hyperuricemia. These markers can be combined to specifically distinguish four subtypes of hyperuricemia: renal overload type, renal poor excretion type, mixed type, and other types. The above markers can be used to establish a model for distinguishing clinical subtypes of hyperuricemia;

[0085] 2. The biomarkers and the model for distinguishing clinical subtypes of hyperuricemia described in this application can accurately distinguish the specific subtypes of hyperuricemia patients in actual clinical applications, and carry out targeted treatment, which helps to accelerate the treatment process. BRIEF DESCRIPTION OF THE DRAWINGS

[0086] The drawings described herein are used to provide a further understanding of the present application and constitute a part of the present application. The illustrative embodiments of the present application and their descriptions are used to explain the present application and do not constitute an improper limitation on the present application. In the drawings:

[0087] Figure 1 Figure 2 shows the variables related to the clinical manifestations of gout in the multivariate regression analysis, where A: OR value of the variables related to blood uric acid level; B: OR value of the variables related to frequent gout; C: OR value of the variables related to subcutaneous tophi; D: OR value of the variables related to eGFR < 60 mL / min / 1.73 m 2 OR values ​​of relevant variables;

[0088] Figure 2 The OR value diagram of genetic susceptibility associated with ROL type (A), UUE type (B) and mixed type (C), among which combination 1 includes 7 SNPs significantly associated with ROL type; combination 2 includes 10 SNPs significantly associated with RUE type; combination 3 includes 7 SNPs significantly associated with mixed type. Due to the small sample size, other types were not analyzed;

[0089] Figure 3 The ROC curve of the ROL subtype prediction model was obtained. All variables significantly associated with the ROL type included whether the PRS was medium-risk / high-risk, disease duration, BMI, SU, cholesterol, age, HDL, chronic renal insufficiency (CKD stage 3 and above), tophi, diabetes, hypertension, and smoking history.

[0090] Figure 4 It is the calibration curve of ROL type prediction model;

[0091] Figure 5 The ROC curve of the prediction model for RUE subtype was obtained. All variables including PRS significantly associated with RUE type were medium / high risk, disease duration, BMI, SU, cholesterol, age, chronic renal insufficiency (CKD stage 3 and above), tophi, fatty liver, diabetes, hypertension, and kidney stones.

[0092] Figure 6 It is the calibration curve of RUE type prediction model;

[0093] Figure 7The ROC curve of the prediction model of whether it is a mixed type, including all variables significantly associated with the mixed type, including whether the PRS is medium risk / high risk, disease course, BMI, SU, cholesterol, age, triglycerides, chronic renal insufficiency (CKD stage 3 and above), tophi, fatty liver, and smoking;

[0094] Figure 8 It is the calibration curve of the hybrid prediction model;

[0095] Among them, Age, Sex, BMI, Disease duration, Serum urate, Urine pH, Triglyceride, Total cholesterol, blood glucose, Frequent gout flare, Alcohol, Regular exercise, Subcutaneous tophi, NAFLD, non-alcoholic fatty liver disease, Nephrolithiasis, and hypertension. DETAILED DESCRIPTION

[0096] In order to more clearly explain the overall concept of the present application, the following is described in detail in conjunction with the accompanying drawings of the specification by way of embodiment. In the following description, a large number of specific details are provided to provide a more thorough understanding of the present invention. However, it is obvious to those skilled in the art that the present invention can be implemented without one or more of these details. In other examples, in order to avoid confusion with the present invention, some technical features well known in the art are not described.

[0097] If no specific conditions are specified in the examples, the experiments were carried out according to conventional conditions or conditions recommended by the manufacturer.

[0098] Unless otherwise specified, in the following embodiments, the reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.

[0099] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the field of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related fields, and can be specifically performed according to Molecular Cloning: A Laboratory Manual (Fourth Edition).

[0100] This study was approved by the Ethics Committee of Qingdao University Hospital in China.

[0101] The diagnosis of gout was established according to the 2015 American College of Rheumatology / European League of Associations Against Rheumatism (ACR / EULAR) gout classification criteria. The hyperuricemia subtype was defined as: UUE>600 mg / d / 1.73 m 2 , FEUA ≥ 5.5% is ROL type, UUE ≤ 600 mg / d / 1.73 m 2 , FEUA < 5.5% is RUE type, UUE > 600 mg / d / 1.73 m 2 , FEUA < 5.5% is mixed type, UUE ≤ 600 mg / d / 1.73 m 2 , FEUA ≥ 5.5% is other types.

[0102] Patients who were followed regularly at two hospital clinics between September 2016 and August 2022 were screened, and those who could be regularly visited after 14 days were enrolled. Patients who met the ACR / EULAR classification criteria and gave written informed consent were eligible for this study. The classification criteria required at least 1 occurrence of swelling, pain, or tenderness in peripheral joints or bursae. A threshold score ≥8 classified individuals as gout patients. All participants were required to undergo a 14-day washout period, discontinue any medications with uric acid-lowering effects and follow a low-purine diet before 24-h urine and fasting blood collection. Patients with severe cardiovascular disease, cerebrovascular disease, kidney disease, diabetes, cancer, other inflammatory arthritis, or severe gout who could not tolerate the washout period would be excluded. Participants were divided into four hyperuricemia subtypes based on 24-h urinary uric acid excretion (UUE) and fractional excretion of uric acid (FEUA).

[0103] General information including age, disease duration, height, weight, body mass index (BMI, kg / m 2 ), systolic blood pressure (SBP), diastolic blood pressure (DBP), presence of subcutaneous tophi, gout attacks, smoking history (≥20 packs of cigarettes or ≥1 cigarette in a lifetime for ≥1 year), alcohol history (alcohol intake ≥1 week for 6 months), and related diseases such as hypertension, diabetes, non-alcoholic fatty liver disease, and hyperlipidemia. Gout attacks were defined as patient-reported pain visual analogue score > (0-10 scale). Frequent gout was defined as ≥2 gout attacks per year.

[0104] After the 14-day washout period, 24-hour urine and fasting blood were collected, and biochemical indicators such as serum uric acid (SU), blood glucose (Glu), triglycerides (TG), total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), creatinine (Cr), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured using an automatic biochemical analyzer (TBA-40FR, Toshiba, Japan). Proteinuria was detected using an automatic urine analyzer (AX-4280, ARKRAY, Japan), and a concentration exceeding 0.15 g / d was considered positive for proteinuria. FEUA and UUE were calculated based on 24-hour urine volume and 24-hour uUA and uCr. FEUA = uUA / uCr × sCr / sUA × 100%, UUE = uUA × 24-hour urine volume / [0.0061 × height (cm) + 0.0128 × weight (kg) - 0.1529) × 1.73 (mg / d / 1.73m 2 )].

[0105] According to the criteria of the Chinese Diabetes Society, metabolic syndrome is defined as the presence of three or more of the following four components: (1) body mass index (BMI) ≥ 25 kg / m 2 ; (2) fasting blood glucose (Glu) ≥6.1mmol / L or Glu ≥7.8mmol / L 2 hours after meal; (3) blood pressure ≥140 / 90mm Hg; or (4) fasting serum triglycerides (TG) ≥1.7mmol / L, or HDL-C <0.9mmol / L for men or <1.0mmol / L for women. Individuals diagnosed with hypertension or diabetes and using antihypertensive or hypoglycemic drugs met the criteria for hypertension or hyperglycemia. The Zhejiang University (ZJU) nonalcoholic fatty liver disease (NAFLD) diagnostic index was calculated as BMI (kg / m 2 )+fasting blood glucose (mmol / L)+TG (mmol / L)+3×ALT / AST ratio (female+2). TyG index is calculated as Ln[fasting triglyceride (mg / dL)*fasting blood glucose (mg / dL) / 2]. Insulin resistance is assessed by TG / HDL-C ratio and TyG index.

[0106] In the following examples, genomic DNA was extracted from peripheral blood mononuclear cells using SNP genotyping was performed using the II-G384 chip (Agena Bioscience, San Diego, USA).

[0107] The following examples involve primers related to SNP site amplification as shown in Table 1.

[0108] Table 1

[0109]

[0110]

[0111] Example 1 Screening of SNP sites associated with clinical subtypes of hyperuricemia

[0112] In this example, we hypothesized that multiple genetic variants may work together to establish unique clinical features, specifically, clinical subtypes of hyperuricemia. We conducted a cross-sectional observational study of gout patients with clinically defined hyperuricemia to explore the phenotypic and genotypic characteristics between hyperuricemia subtypes.

[0113] In this example, 1240 participants were randomly selected for genotyping of 20 SNPs. The target genetic variation is 20 SNPs that are gout susceptibility loci or associated with SU concentration and / or FEUA in East Asian populations. Another sample set of 2638 gout GWAS Chinese healthy men was used as a control to determine the hyperuricemia clinical subtype-specific SNPs.

[0114] A weighted multi-genetic risk score (PRS) for primary gout (hyperuricemia) subtypes was calculated to assess the cumulative effect of genetic risk on primary gout subtypes.

[0115] The number of risk alleles for each SNP (0, 1 or 2) was weighted by the effect size between the SNP and the primary gout subtype. The individual-level genetic risk score was then derived from the sum of the number of risk alleles present on each SNP, and weighted by the effect size, and summed to form a weighted polygenic score for each individual hyperuricemia clinical subtype model. The higher the polygenic score, the greater the genetic susceptibility of a certain subtype. That is, the PRS calculation method is the number of risk alleles multiplied by the effect size (log OR) of the risk allele. Participants were divided into low (lowest quantile), medium (2 quantiles) and high (highest quantile) genetic risk groups according to the standardized PRS.

[0116] Based on the results of association analysis between SNPs and clinical subtypes of hyperuricemia, we generated PRS models for different subtypes according to different SNP combinations. Univariate and multivariate logistic regression analyses were applied to estimate the genetic risks between quantiles in each model.

[0117] Specifically, if the data were normally distributed, continuous variables were expressed as mean (standard deviation, SD), and if the data were non-normally distributed, median (interquartile range, IQR) was used. For categorical variables, data were expressed as numbers (percentage, %). General information of subjects of different subtypes was compared, continuous and categorical variables were analyzed by analysis of variance and chi-square test, and skewed distribution variables were analyzed by Kruskal-Wallis test. Pairwise comparisons between groups were performed using 2×2 chi-square test, and significance was corrected by Bonferroni. All tests were two-sided. The differences were statistically significant (P < 0.05).

[0118] Subtype-specific clinical characteristics were evaluated using binary logistic regression analysis in univariate and multivariate analyses. The dependent variable was each subtype label (1 = target subtype, 0 = other three subtypes). All variables with P < 0.20 in the univariate regression analysis were included in the multivariate regression model. ORs and 95% CIs were estimated. Linear regression analysis was performed to evaluate whether the patient's subtype affected SU levels, and logistic regression analysis was performed to evaluate whether the patient's subtype affected gout flares, subcutaneous tophi, or CKD stage.

[0119] In the allele and genotype frequency analyses, comparisons between subtypes were performed post hoc with Bonferroni correction. P < 0.05 was considered statistically significant. A 2 × 2 chi-square test was used for pairwise comparisons between groups.

[0120] Univariate and multivariate logistic regression models were used to examine the association of genetic risk of SNPs combinations with clinical subtypes of hyperuricemia. The dependent variable was each subtype label (1 = target subtype, 0 = other three subtypes), and the independent variables included PRS and covariates. The multivariate model was adjusted for age, BMI, disease duration, SU, and other clinical variables, with P < 0.20 in the univariate analysis.

[0121] In this example, logistic regression analysis (generalized linear model) was used to evaluate the correlation between SNPs and clinical subtypes of gout and hyperuricemia; the dependent variable was gout marker (case = 1, control = 0), and the independent variables included the estimated genotype and covariates of each SNP. PLINK (http: / / www.bwh.harvard.edu / plink / ) was used to perform association analysis between SNPs and four subtypes of gout and hyperuricemia. Bonferroni correction was used to adjust the genetic p value. Assume that bilateral p<0.0025 is significant for SNP association analysis. Multivariate logistic regression model was used to estimate the odds ratios (ORs) and 95% CI of gout and genetic risk and clinical subtypes of hyperuricemia. The univariate analysis adjusted the model for variables with P<0.20 such as age, BMI, disease duration, and serum uric acid.

[0122] Finally, a total of 5385 gout patients were screened, 512 patients were excluded due to withdrawal of informed consent, severe comorbidities, or gout attacks during the washout period, 4873 patients were typed for hyperuricemia, and 1240 patients were tested for targeted SNP gene loci ( Figure 1 Among the 4873 participants, 428 (8.8%) were ROL type, 2970 (60.9%) were RUE type, 1124 (23.1%) were mixed type, and 351 (7.2%) were other types. There were significant differences in UUE among the four subtypes (mean [SD] 831.9 [224.9], 436.8 [96.3], 761.7 [183.8], 486.9 [88.6], P < 0.001), and there were also significant differences in FEUA values ​​(mean [SD] 6.8 [1.9], 3.7 [0.8], 4.3 [0.7], 6.5 [1.3], P < 0.001) (Table 2).

[0123] Table 2 Clinical and biochemical characteristics of the four hyperuricemia subtypes

[0124]

[0125]

[0126] Note: The numerical marking method indicates the difference. A, B, C, D, the four groups are compared two by two. If there is any same letter, there is no significant difference between the two groups.

[0127] BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, HDL-C: high-density lipoprotein; ALT: alanine aminotransferase; AST: aspartate aminotransferase; eGFR: estimated glomerular filtration rate; ZJU index: fatty liver index; FEUA: fractional uric acid excretion; UUE: 24-hour urine uric acid excretion; NAFLD: non-alcoholic fatty liver disease; CKD> stage 2 means eGFR<60 mL / min / 1.73 m 2 As shown in Table 2, among the genotyped participants, 108 (8.7%) were classified as ROL type, 788 (63.5%) were classified as RUE type, 291 (23.5%) were classified as mixed type, and 53 (4.3%) were classified as other types. This subtype distribution is similar to other studies, and the consistency between the two means that this classification system is reasonable.

[0128] The 1240 subjects mentioned above were genotyped for 20 SNPs, as shown in Tables 3 and 4. Among all gout patients, 13 loci showed association at the genome-wide significant level, namely ABCG2, MUC1, GCKR, SLC2A9 / GLUT9 (2 loci), SLC22A9 / OAT7, PLA2G16, FLRT1, NRXN2 / URAT1 (2 loci), AIP, ALDH2 and COMMD4, and the remaining 7 loci had no association, namely rs1797052 of PDZK1, rs2762353 of SLC17A1, rs17145750 of MLXIPL, rs79105258 of CUX2, rs4966024 of IGF1R, rs73575095 of MAF and rs9895661 of BCAS3.

[0129] Table 3 Allele frequencies of four hyperuricemia subtypes

[0130]

[0131] Note: The numerical notation indicates the difference. When comparing groups a and b, if there is any identical letter between the two groups, there is no significant difference between the two groups.

[0132] Table 4 SNP sites significantly associated with four hyperuricemia subtypes

[0133]

[0134]

[0135] Note: Two-sided P < 2.5 × 10 -3 The association analysis between the risk loci and the four clinical subtypes of gout and hyperuricemia was considered statistically significant.

[0136] In summary, the relevant SNP sites can be divided into the following four groups according to different subtypes.

[0137] Group 1: rs4072037 of MUC1, rs3775948 of SLC2A9, rs2231142 of ABCG2, rs11231463 of SLC22A9, rs7928514 of PLA2G16, rs57633992 of NRXN2 and rs11227805 of AIP were significantly associated with renal overload type.

[0138] Group 2: rs4072037 of MUC1, rs7679724 and rs3775948 of SLC2A9, rs2231142 of ABCG2, rs11231463 of SLC22A9, rs7928514 of PLA2G16, rs641811 of FLRT1, rs57633992 of NRXN2, rs671 of ALDH2, and rs73436803 of COMMD4 were significantly associated with the renal malabsorption type.

[0139] Group 3: rs4072037 of MUC1, rs1260326 of GCKR, rs3775948 of SLC2A9, rs2231142 of ABCG2, rs7928514 of PLA2G16, rs641811 of FLRT1, and rs57633992 of NRXN2 were significantly associated with the mixed type.

[0140] Group 4: rs3775948 of SLC2A9, rs2231142 of ABCG2, rs11231463 of SLC22A9, and rs7928514 of PLA2G16 were significantly associated with other types.

[0141] PRS is calculated by multiplying the number of risk alleles (0, 1, or 2) by the corresponding gout effect size (log odds) of each risk allele signal, as shown in the formula PRS = SNP (0, 1, 2) × logOR, and the OR values ​​can be seen in Table 4. These weights are based on the results of association analysis of SNP variations and subtypes. Three PRS models (MODEL1, MODEL2, and MODEL3) were generated based on the combination of subtype-specific SNPs in all subtypes. Among them, higher weighted PRS indicates that certain hyperuricemia subtypes have a higher genetic susceptibility to gout. According to the PRS of a certain model, participants were divided into low (lowest tertile), medium (middle tertile), and high (highest tertile) genetic risk categories.

[0142] MODEL1:

[0143] The risk alleles include rs4072037 of MUC1, rs3775948 of SLC2A9, rs2231142 of ABCG2, rs11231463 of SLC22A9, rs7928514 of PLA2G16, rs57633992 of NRXN2 and rs11227805 of AIP, i.e., the above 1 group of SNP loci combination. The PRS of MODEL1 is the sum of the PRS values ​​of the above related loci. When PRS < 1.71, it is a low risk of renal overload type, PRS between 1.71-2.19 is a medium risk of renal overload type, and PRS > 2.19 is a high risk of renal overload type.

[0144] MODEL2:

[0145] The risk alleles include rs4072037 of MUC1, rs7679724 and rs3775948 of SLC2A9, rs2231142 of ABCG2, rs11231463 of SLC22A9, rs7928514 of PLA2G16, rs641811 of FLRT1, rs57633992 of NRXN2, rs671 of ALDH2, and rs73436803 of COMMD4, i.e., the combination of the above two groups of SNP loci. The PRS of MODEL2 is the sum of the PRS values ​​of the above related loci. When PRS < 2.95, it is a low risk of renal malabsorption type, PRS between 2.95-3.36 is a medium risk of renal malabsorption type, and PRS > 3.36 is a high risk of renal malabsorption type.

[0146] MODEL3:

[0147] The risk alleles include rs4072037 of MUC1, rs1260326 of GCKR, rs3775948 of SLC2A9, rs2231142 of ABCG2, rs7928514 of PLA2G16, rs641811 of FLRT1, and rs57633992 of NRXN2, i.e., the above three groups of SNP loci. The PRS of MODEL3 is the sum of the PRS values ​​of the above related loci. When PRS < 1.85, it is a mixed type of low risk, PRS between 1.85-2.27 is a mixed type of medium risk, and PRS > 2.27 is a mixed type of high risk.

[0148] Figure 2 The relationship between subtypes and joint exposures of SNP combinations and genetic susceptibility levels is shown. Figure 2 As shown, the average PRS of SNPs in group 1 were ROL subtype (2.72±0.64), RUE subtype (1.76±0.39), and mixed type (2.29±0.45) (P<0.001). The average PRS of SNPs in group 2 were ROL subtype (3.45±0.62), RUE subtype (3.20±0.43), and mixed type (2.94±0.49) (P<0.001). The average PRS of SNPs in group 3 were ROL subtype (2.60±0.51), RUE subtype (1.90±0.39), and mixed type (2.40±0.48) (P<0.001).

[0149] High genetic susceptibility of all SNP groups was independently associated with the ROL group, and moderate genetic susceptibility of one SNP group was also associated with the ROL subtype, with the highest OR value ( Figure 2A). The medium and high genetic susceptibility of the two groups of SNPs are independently associated with RUE subtypes ( Figure 2 B) The medium and high genetic susceptibility of group 1 and group 3 SNPs are independently associated with the mixed type ( Figure 2 C).

[0150] in conclusion:

[0151] In this example, the SNP site combination for identifying the four clinical subtypes of hyperuricemia as described above was obtained.

[0152] Specifically, a first biomarker combination for identifying renal overload type, wherein the first biomarker combination consists of rs2231142, rs3775948, rs11231463, rs7928514, rs57633992 and rs4072037;

[0153] A second biomarker combination for identifying renal poor excretion type, wherein the second biomarker combination consists of rs2231142, rs3775948, rs11231463, rs7928514, rs57633992, rs4072037, rs7679724, rs671, rs73436803 and rs641811;

[0154] a third biomarker combination for identifying a mixed type, the third biomarker combination consisting of rs2231142, rs3775948, rs7928514, rs57633992, rs4072037, rs1260326, and rs641811;

[0155] The fourth biomarker combination for identifying other types consists of rs2231142, rs3775948, rs11231463, and rs7928514.

[0156] Moreover, among the 20 targeted SNPs, 3 loci (rs2231142 of ABCG2, rs3775948 of SLC2A9, and rs7928514 of PLA2G16) were shared among all subtypes. The related gene functions were mainly related to SU regulation, such as intestinal urate excretion (ABCG2), renal urate excretion (SLC2A9 / GLUT9, NRXN2 / URAT1), hepatic urate secretion (SLC22A9 / OAT7), and lipid metabolism and metabolic syndrome (PLA2G16).

[0157] Three loci (rs11231463 of SLC22A9, rs4072037 of MUC1, and rs57633992 of NRXN2) were shared by the three subtypes and were associated with ROL, UUE, and mixed types, but not with the other types.

[0158] In addition, there are subtype-specific loci: rs11227805 of AIP in ROL type; rs7679724 of SLC2A9, rs641811 of FLRT1, rs671 of ALDH2, and rs73436803 of COMMD4 in RUE type; rs1260326 of GCKR and rs641811 of FLRT1 in mixed type. The rs1127805 risk variant of AIP is ROL-specific, and the gene product is related to nutrition and metabolism, including purine metabolism and urate production, which makes it possible that this locus is a ROL-specific locus. rs7679724 of SLC2A9, rs671 of ALDH2, rs641811 / FLRT1 and rs73436803 / COMM4 are RUE-specific risk loci, which are associated with proximal tubule reabsorption, kidney disease, etc.; rs7679724G allele is negatively correlated with FEUA. rs1260326 / GCKR is a mixed risk variant site, which is associated with glucose kinase regulatory subprotein: insulin resistance.

[0159] Example 2 Prediction model related to clinical subtypes of hyperuricemia

[0160] All statistical analyses in this example were performed using R version 4.2.3 and python version 3.11.4.

[0161] 1. Prediction model of renal overload

[0162] Methods: Using logistic regression, possible predictors of gout as ROL subtype were identified from the following covariates according to their biological relevance: disease duration, BMI, serum uric acid, cholesterol, age, high-density lipoprotein, chronic renal insufficiency, tophi, diabetes, hypertension, smoking history (1 yes, 0 no), and whether the PRS of the SNP loci significant for ROL subtype (rs2231142, rs3775948, rs11231463, rs7928514, rs57633992, and rs4072037) were intermediate / high risk. Variables with P value < 0.2 were accepted in the model. Results are expressed as odds ratio (OR) and 95% confidence interval (95% CI). Subsequently, receiver operating characteristic (ROC) curve analysis was performed, and each independent variable was included in the multivariate logistic regression to evaluate the predictive effect of whether it was ROL subtype, with P value < 0.005 as significant.

[0163] The coefficient of the variable BMI is -0.008, the OR value is 0.992, and the p value is 0.851, which is not significant, meaning that it has no impact on the results.

[0164] The coefficient of the variable SU is -0.495, the OR value is 0.61, and the p value is <0.001, which is significant, meaning that it will have an impact on the results.

[0165] The coefficient of the variable CH is 0.093, the OR value is 1.098, and the p value is 0.469, which is not significant, meaning that it has no impact on the results.

[0166] The coefficient of the variable age is 0.022, the OR value is 1.022, and the p value is 0.053, which is not significant, meaning that it has no impact on the results.

[0167] The coefficient of the variable HDL is -0.024, the OR value is 0.976, and the p value is 0.959, which is not significant, meaning that it has no impact on the results.

[0168] The coefficient of the variable whether there is chronic renal insufficiency is 1.285, the OR value is 3.613, and the p value is 0.113, which is not significant, meaning that it will not affect the results.

[0169] The coefficient of the variable whether or not there is tophi is 0.423, the OR value is 1.526, and the p value is 0.19, which is not significant, meaning that it will not affect the results.

[0170] The coefficient of the variable whether or not there is diabetes is 0.823, the OR value is 2.276, and the p value is 0.006, which is significant, meaning that it will have an impact on the results.

[0171] The coefficient of the variable whether or not there is hypertension is 0.241, the OR value is 1.272, and the p value is 0.358, which is not significant, meaning that it will not affect the results.

[0172] The coefficient of the variable whether there is a smoking history is -0.104, the OR value is 0.901, and the p value is 0.677, which is not significant, meaning that it will not affect the results.

[0173] The risk coefficient in SNPs MODEL1 is 1.429, the OR value is 3.144, and the p value is 0.005, which is significant, meaning that it will have an impact on the results.

[0174] The high-risk coefficient of SNPs MODEL1 is 3.197, the OR value is 9.628, and the p value is <0.001, which is significant, meaning that it will have an impact on the results.

[0175] Constructing the Logistic Regression Formula

[0176] According to the regression coefficient (β value) in the logistic regression analysis, the logistic regression formula can be constructed.

[0177]

[0178] The probability P(Y=1) can be solved from the logit function:

[0179]

[0180] Where X is an independent variable (such as age, gender, uric acid, etc.), β is the corresponding regression coefficient of each independent variable in the logistic regression, and P(Y=1) is the probability that the patient is a gout patient of this subtype.

[0181] The AUC of the above model is 0.84 ( Figure 3 ), among the variables included in the model, the coefficient of the variable course of disease was 0.011, the OR value was 1.011, and the p value was 0.632, which was not significant, meaning that it would not affect the results.

[0182] The Brier Score in the calibration curve is: 0.063 ( Figure 4 ).

[0183] Cox-Snell R2 is: 0.307, Nagelkerke R2 is: 0.138.

[0184] The Hosmer and Lemeshow goodness of fit (GOF) test method was used to evaluate the goodness of fit of the logistic regression model, with a P value of 0.515 and a statistic of 7.206.

[0185] The R version is: 4.2.3, the main package versions involved are pROC: 1.18.5, rms: 6.7.1, forestploter: 1.1.1, ResourceSelection: 0.3.6, dplyr: 1.1.4, and MASS: 7.3.60.

[0186] The results of the logistic regression analysis are shown in Table 5 .

[0187] Table 5

[0188]

[0189] risk

[0190] 2. Prediction model of poor renal excretion

[0191] Methods: Using logistic regression, we identified the possible predictors of gout as RUE subtype from the following covariates according to their biological relevance: disease duration, BMI, SU, cholesterol, age, chronic renal insufficiency (CKD stage 3 and above), tophi, fatty liver, diabetes, hypertension, kidney stones, and whether the PRS of the SNP loci significant for RUE subtype (rs2231142, rs3775948, rs11231463, rs7928514, rs57633992, rs4072037, rs7679724, rs671, rs73436803, and rs641811) were intermediate / high risk. Variables with P value < 0.2 were accepted in the model. Results are expressed as odds ratio (OR) and 95% confidence interval (95% CI). Subsequently, receiver operating characteristic (ROC) curve analysis was performed, and each independent variable was included in the multivariate logistic regression to evaluate whether it had a predictive effect on ROL subtypes, with a P value < 0.005 being significant.

[0192] The coefficient of the variable BMI is -0.041, the OR value is 0.96, and the p value is 0.053, which is not significant, meaning that it has no impact on the results.

[0193] The coefficient of the variable SU is -0.105, the OR value is 0.9, and the p value is 0.035, which is significant, meaning that it will have an impact on the results.

[0194] The coefficient of the variable cholesterol is -0.122, the OR value is 0.885, and the p value is 0.088, which is not significant, meaning that it will not affect the results.

[0195] The coefficient of the variable age is -0.002, the OR value is 0.998, and the p value is 0.787, which is not significant, meaning that it has no impact on the results.

[0196] The coefficient of the variable whether there is chronic renal insufficiency is 0.071, the OR value is 1.073, and the p value is 0.913, which is not significant, meaning that it will not affect the results.

[0197] The coefficient of the variable whether or not there is tophi is -0.12, the OR value is 0.887, and the p value is 0.543, which is not significant, meaning that it will not affect the results.

[0198] The coefficient of the variable whether there is fatty liver is -0.22, the OR value is 0.803, and the p value is 0.234, which is not significant, meaning that it will not affect the results.

[0199] The coefficient of the variable whether or not there is diabetes is -0.824, the OR value is 0.438, and the p value is 0, which is significant, meaning that it will have an impact on the results.

[0200] The coefficient of the variable whether or not there is hypertension is -0.169, the OR value is 0.845, and the p value is 0.251, which is not significant, meaning that it will not affect the results.

[0201] The coefficient of the variable whether or not there is kidney stone is -0.271, the OR value is 0.763, and the p value is 0.148, which is not significant, meaning that it will not affect the results.

[0202] The risk coefficient in Model 2SNPs is 0.526, the OR value is 1.642, and the p value is <0.001, which is significant, meaning that it will have an impact on the results.

[0203] The high-risk coefficient of Model 2SNPs is 0.791, the OR value is 2.175, and the p value is <0.001, which is significant, meaning that it will have an impact on the results.

[0204] Constructing the Logistic Regression Formula

[0205] According to the regression coefficient (β value) in the logistic regression analysis, the logistic regression formula can be constructed.

[0206]

[0207] The probability P(Y=1) can be solved from the logit function:

[0208]

[0209] Where X is an independent variable (such as age, gender, uric acid, etc.), β is the corresponding regression coefficient of each independent variable in the logistic regression, and P(Y=1) is the probability that the patient is a gout patient of this subtype.

[0210] The AUC of the above model is 0.65 ( Figure 5 ), among the variables included in the model, the coefficient of the variable course of disease was -0.003, the OR value was 0.997, and the p value was 0.834, which was not significant, meaning that it would not affect the outcome.

[0211] The Brier Score in the calibration curve is: 0.209 ( Figure 6 ).

[0212] Cox-Snell R2 is: 0.094, Nagelkerke R2 is: 0.068.

[0213] The Hosmer and Lemeshow goodness of fit (GOF) test method was used to evaluate the goodness of fit of the logistic regression model, with a P value of 0.501 and a statistic of 7.334.

[0214] The R version is: 4.2.3, the main package versions involved are pROC: 1.18.5, rms: 6.7.1, forestploter: 1.1.1, ResourceSelection: 0.3.6, dplyr: 1.1.4, and MASS: 7.3.60.

[0215] The results of the logistic regression analysis are shown in Table 6 .

[0216] Table 6

[0217]

[0218]

[0219] 3. Hybrid prediction model

[0220] Methods: Using logistic regression, possible predictors of mixed gout subtype were identified from the following covariates according to their biological relevance: disease duration, BMI, SU, cholesterol, age, triglycerides, chronic renal insufficiency (CKD stage 3 and above), tophi, fatty liver, smoking, and intermediate / high risk of PRS of SNP loci significant for mixed subtype (rs2231142, rs3775948, rs7928514, rs57633992, rs4072037, rs1260326, and rs641811). Variables with P value < 0.2 were accepted in the model. Results are expressed as odds ratio (OR) and 95% confidence interval (95% CI). Subsequently, receiver operating characteristic (ROC) curve analysis was performed, and each independent variable was included in the multivariate logistic regression to evaluate the predictive effect of ROL subtype, with P value < 0.005 as significant.

[0221] The coefficient of the variable BMI is 0.071, the OR value is 1.074, and the p value is 0.002, which is significant, meaning that it will have an impact on the results.

[0222] The coefficient of the variable SU is 0.23, the OR value is 1.259, and the p value is 0, which is significant, meaning that it will have an impact on the results.

[0223] The coefficient of the variable cholesterol is 0.163, the OR value is 1.177, and the p value is 0.062, which is not significant, meaning that it will not affect the results.

[0224] The coefficient of the variable age is -0.002, the OR value is 0.998, and the p value is 0.765, which is not significant, meaning that it has no impact on the results.

[0225] The coefficient of the variable triglyceride is -0.025, the OR value is 0.975, and the p value is 0.656, which is not significant, meaning that it will not affect the results.

[0226] The coefficient of the variable whether there is chronic renal insufficiency is -14.679, the OR value is 0, and the p value is 0.97, which is not significant, meaning that it will not affect the results.

[0227] The coefficient of the variable whether or not there is tophi is -0.254, the OR value is 0.776, and the p value is 0.273, which is not significant, meaning that it will not affect the results.

[0228] The coefficient of the variable whether there is a smoking history is 0.415, the OR value is 1.514, and the p value is 0.01, which is significant, meaning that it will have an impact on the results.

[0229] The risk coefficient in SNPs MODEL3 is 0.557, the OR value is 1.756, and the p value is 0.012, which is significant, meaning that it will have an impact on the results.

[0230] The high-risk coefficient of SNPs MODEL3 is 1.88, the OR value is 6.32, and the p value is <0.001, which is significant, meaning that it will have an impact on the results.

[0231] The coefficient of the variable whether there is fatty liver is 0.497, the OR value is 1.644, and the p value is 0.016, which is significant, meaning that it will have an impact on the results.

[0232] Constructing the Logistic Regression Formula

[0233] According to the regression coefficient (β value) in the logistic regression analysis, the logistic regression formula can be constructed.

[0234]

[0235] The probability P(Y=1) can be solved from the logit function:

[0236]

[0237] Where X is an independent variable (such as age, gender, uric acid, etc.), β is the corresponding regression coefficient of each independent variable in the logistic regression, and P(Y=1) is the probability that the patient is a gout patient of this subtype.

[0238] The AUC of the above model is 0.76 ( Figure 7 ), among the variables included in the model, the coefficient of the variable course of disease was 0.007, the OR value was 1.007, and the p value was 0.693, which was not significant, meaning that it would not affect the results.

[0239] The Brier Score in the calibration curve is: 0.156 ( Figure 8 ).

[0240] Cox-Snell R2 is: 0.239, Nagelkerke R2 is: 0.162.

[0241] The Hosmer and Lemeshow goodness of fit (GOF) test method was used to evaluate the goodness of fit of the logistic regression model, with a P value of 0.089 and a statistic of 13.731.

[0242] The R version is: 4.2.3, the main package versions involved are pROC: 1.18.5, rms: 6.7.1, forestploter: 1.1.1, ResourceSelection: 0.3.6, dplyr: 1.1.4, and MASS: 7.3.60.

[0243] The results of the logistic regression analysis are shown in Table 7.

[0244] Table 7

[0245]

[0246]

[0247] In summary, among the three prediction models, the one with the highest probability of P(Y=1) is the most likely subtype of the patient.

[0248] The above results demonstrate that the SNP site combinations of Group 1, Group 2 and Group 3 obtained in Example 1 can be used for the classification of primary gout hyperuricemia subtypes.

[0249] The above is only an embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various changes and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application should be included in the scope of the claims of the present application.

Claims

1. A biomarker for distinguishing clinical subtypes of hyperuricemia, characterized in that: The clinical subtypes of hyperuricemia include renal overload type, renal poor excretion type, mixed type and other types, and the biomarker includes at least one SNP site from SNP1 site to SNP12 site; The rs number of SNP1 site is rs2231142, the rs number of SNP2 site is rs3775948, the rs number of SNP3 site is rs11231463, the rs number of SNP4 site is rs7928514, the rs number of SNP5 site is rs57633992, the rs number of SNP6 site is rs4072037, the rs number of SNP7 site is rs11227805, the rs number of SNP8 site is rs7679724, the rs number of SNP9 site is rs671, the rs number of SNP10 site is rs73436803, the rs number of SNP11 site is rs1260326, and the rs number of SNP12 site is rs641811.

2. The biomarker according to claim 1, characterized in that The biomarkers include: A first biomarker combination for identifying kidney overload type, wherein the first biomarker combination includes at least one SNP site among SNP1, SNP2, SNP3, SNP4, SNP5, and SNP6; A second biomarker combination for identifying poor renal excretion type, wherein the second biomarker combination includes at least one SNP site among SNP1, SNP2, SNP3, SNP4, SNP5, SNP6, SNP8, SNP9, SNP10, and SNP12; A third biomarker combination for identifying a mixed type, wherein the third biomarker combination includes at least one SNP site among SNP1, SNP2, SNP4, SNP5, SNP6, SNP11, and SNP12; A fourth biomarker combination for identifying other types, wherein the fourth biomarker combination includes at least one SNP site among SNP1, SNP2, SNP3, and SNP4.

3. A primer or probe for detecting the biomarker according to claim 1, characterized in that: The primers use the nucleotide sequence where the biomarker is located as the target sequence and are used for specific amplification of the target sequence; the probes specifically capture the nucleotide sequence where the biomarker is located.

4. A kit for distinguishing clinical subtypes of hyperuricemia, characterized in that: The kit contains the primer or probe according to claim 3.

5. The kit according to claim 4, characterized in that The kit also includes reagents used in any one of the following methods, including fluorescent PCR, PCR amplification, digital PCR, liquid phase chip, second generation sequencing, and third generation sequencing, or a combination thereof.

6. Use of the biomarker according to claim 1 or 2, or the primer or probe according to claim 3, or the kit according to claim 4 or 5 in the preparation of a product for distinguishing clinical subtypes of hyperuricemia.

7. A model for distinguishing clinical subtypes of hyperuricemia, characterized in that: The model includes: a data acquisition module, at least for acquiring a sample data set; a sequencing module, at least for obtaining sequencing data of the biomarkers of the sample as described in claim 1 or 2; a data comparison module, at least for comparing the sequencing data with a reference sequence; and a result determination module, at least for calculating a prediction score threshold through statistical model analysis to determine the clinical subtype of hyperuricemia in the sample to be tested.

8. The model according to claim 7, characterized in that The clinical subtypes of hyperuricemia include renal overload type, renal poor excretion type, mixed type and other types.

9. An information data processing terminal, characterized in that: The information data processing terminal includes a memory, a processor, and a computer program stored in the memory and executable on the processor, wherein the processor implements the following steps when executing the computer program: (a) obtaining sequencing data of the biomarker according to claim 1 or 2 in the sample to be tested; (b) calculating a score by constructing a logistic regression model; (c) determining the clinical subtype of hyperuricemia according to the score.

10. A computer-readable storage medium, characterized in that: The storage medium stores a computer program, and when the computer program is executed by the processor, the following steps are implemented: (a) obtaining sequencing data of the biomarker according to claim 1 or 2 in the sample to be tested; (b) calculating a score by constructing a logistic regression model; (c) determining the clinical subtype of hyperuricemia according to the score.

Citation Information

Patent Citations

  • Molecule associated with onset of gout, and method and kit for evaluating diathesis of uric acid-related diseases and inflammation-related diseases, and inspection object and drug

    CN106133136A

  • SNP marker associated with auxiliary diagnosis of esophageal cancer

    CN110218793A

  • Method for improving typing judgment accuracy of gout patient

    CN114464310A